Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Supreme Court Should Pass On Zarxio, Wait For Another Biosimilar Suit, Amgen Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Sandoz's petition challenging biosimilar launch notification requirements isn't urgent, Amgen argues, but if court takes up case, Amgen also wants it to rule on whether patent dance is optional.


Related Content

Amgen Can't Stop Avastin Biosimilar 'Patent Dance' After Opting In, Genentech Says


Related Companies